SACRAMENTO, Calif. - eTradeWire -- The ROS1ders is pleased to issue their annual Request for Application (RFA) to study ROS1-positive (ROS1+) cancer.

"ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer," said Janet Freeman-Daily, MS, co-founder and president of The ROS1ders. "While oral targeted therapies are approved to treat it, the drugs don't work for everyone, and they eventually stop working. We need more research to learn more about ROS1 biology, find better treatments, and improve quality of life and survival for all patients with this disease."

In its third year, the ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward research projects focused on ROS1+ cancer. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research and is open to investigators who hold a doctorate degree (or equivalent) and a faculty appointment at an academic or non-profit research institution anywhere in the world. The ROS1ders plan to support three seed grant projects in 2025.

More on eTradeWire News

• Rich Florals Celebrates Grand Opening of Luxury Rose Studio in Woodbridge with Mayor McCormac
• Home Service Contractors Missing Out on Thousands of Monthly Searches, New Analysis Show
• Kindred Spirits: A Devotional for Those Loving Someone Through Addiction
• Tawanna Chamberlain Launches New Book, Outsized Ambition: The Blueprint for Going Beyond!
• Global Missions Chief, Anton Williams, Leads Grand Rapids MI Based Company to Updated MedTech

"Seed grants, as the name suggests, allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the real seeds of breakthroughs."

The award program uses a two-step application process. An applicant must first submit a letter of intent (LOI) due March 17, 2025. A subset of those applicants will be invited to submit a full application due June 23, 2025. Award recipients will be announced in early fall. For more information, visit https://theros1ders.org/seed-grant-program.

About the ROS1ders

The ROS1ders, Inc. is a non-profit public benefit corporation that brings together a global group of patients and their family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Founded in 2015 by ROS1+ lung cancer patients, it is the largest collection of ROS1+ patients and caregivers in the world, with hundreds of members from dozens of countries. The organization is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Please visit theros1ders.org to learn more.

More on eTradeWire News

• bisco opens 53rd Facility in Chihuahua, Mexico
• Advanced Security Corp. (dba ASC Private Security) Awarded GSA Multiple Award Schedule Contract
• Turf Supply Depot Announces Grand Opening in Nashville, Providing Premium Synthetic Grass Supplies
• DJ Cazel: Founder & Creator of Souldies
• Spirit of Creativity Celebrated with Gold for Destination: Scientology, Amsterdam at Viddy Awards